Navigation Links
Ground Zero Pharmaceuticals Announces Expansion of Global Consulting in Somatic Cell Therapies

IRVINE, Calif., Oct. 5 /PRNewswire/ -- GZP is pleased to announce that it has expanded its capabilities for strategic regulatory and product development support of gene therapy and somatic cell therapies, including treatment vaccines for cancer and other serious or life-threatening diseases.  New senior associates with expertise in manufacturing and clinical development in these expanding areas allow GZP to provide its clients with hands-on guidance through the FDA regulatory review process.  Firms in the US and Australia have already taken advantage of this expertise and are preparing to launch programs in Phase 1, 2 and 3 clinical trials for their "new concept" products.  Two of our staff, Dr. Chaline Brown and Ms. Tisha Templeton, will be attending and presenting this month at the TRX10 and AusBiotech conferences in Brisbane and Melbourne Australia, respectively, and will be available to discuss these added capabilities.  They will be available for partnering meetings as well.

Specifics of these Australian speaking engagements are:

12 October 2010 – Brisbane – TRX10 – "Regulations Pertinent to Pharmacogenomics and Biomarkers in Europe and USA"

20 October 2010 – Melbourne – AusBiotech 2010 - "Dealing with the FDA – What's Hot?"

GZP continues to believe that early, frequent, and creative communication with the FDA (including informal targeted review of specific issues that can slow down development programs at both early and mid-stages) can lead to more successful medical product development, attracting more funding in today's difficult financial climate.

In 2010, GZP increased its global client base at all phases of development across therapeutic areas such as oncology and neurological disease, and created and submitted several INDs.

Pre-pre-IND, pre-IND and mid-phase meetings with the FDA led to acceleration of drug and biologic development programs for our clients.  Our medical device practice also expanded and included consultation with California's Food and Drug Branch as well as the FDA.

According to Evan Siegel, "We are pleased to see that the need for continued review and approval of key medical products and the determination of our clients to be successful has contributed to the recovery from the global financial crisis across industry.  Our client's dedication, loyalty, their referrals, and the excellence of our staff and associates in maintaining an integrated, cohesive and client-specific approach furthers the commitment of GZP to provide the highest quality ethical and knowledgeable consulting."

Based in Irvine, a major biotechnology center in Southern California, Ground Zero Pharmaceuticals, Inc. is a regulatory affairs and product development consulting firm providing strategic and tactical services to the pharmaceutical, biotechnology and medical device industries.  These include regulatory representation and submissions (paper and electronic), strategic medical consulting, preclinical/nonclinical planning, auditing and review of clinical, nonclinical and CMO sites, medical writing, chemistry, manufacturing and controls consulting, clinical assessment, data management, biostatistics, and project management.  GZP has resources throughout the US, Canada, Australia and Europe, and a wholly owned subsidiary in Brisbane and Melbourne, Australia.

Web Site:

For further information please contact Ms. Tisha Templeton, Senior Vice President of Finance and Operations, Ground Zero Pharmaceuticals, Inc., +1-949-852-3666, fax, +1-949-852-3655,

SOURCE Ground Zero Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
2. SPI Pharma Gains Ground in Roquette Patent Dispute
3. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
4. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
5. Groundbreaking International Training Lab to Strengthen Food Safety in U.S. and Globally
6. Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground
7. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
8. Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimers Disease
9. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
10. Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India
11. Grifols Breaks Ground on New National Testing Laboratory
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):